Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Subjects with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

    Cancer Categories
    • Genitourinary (GU)
    Karmanos Trial ID
    • 2024-026
    NCT ID
    • NCT06234605
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary Objectives:

    • To identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability and dose-limiting toxicities (DLTs) of HC-7366 in combination with belzutifan in patients with locally advanced or metastatic RCC with predominantly clear cell histology (ccRCC), irrespective of VHL gene mutation status (combination only).

    Secondary Objectives:

    • To assess the potential antitumor activity of HC-7366 in combination with belzutifan by response, disease stabilization, and survival outcomes by assessing:
      • 1. Overall response rate (ORR) per RECIST v1.1
      • 2. Duration of response (DOR)
      • 3. Disease control rate (DCR: CR or PR or stable disease)
      • 4. Time to Response (TTR)
      • 5. Median progression free survival (PFS) and PFS at six months
      • 6. Median overall survival (OS) and 1-yr OS
    • To determine the plasma concentration and PK parameters following single and multiple doses of HC-7366 alone or in combination with belzutifan administered to patients with locally advanced or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status (PK parameters of both HC-7366 and belzutifan will be measured)
    • To characterize HC-7366 monotherapy and in combination with belzutifan in patients with ccRCC
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266